Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). It works through a reversible, potassium-competitive mechanism to inhibit the H+, K+-ATPase enzyme (the proton pump) in gastric parietal cells. This inhibits the final step of acid secretion, effectively reducing gastric acid production.

Vonoprazan is indicated for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, and reflux esophagitis. It is also used for the prevention of recurrence of gastric or duodenal ulcers during low-dose aspirin or NSAID administration, and as an adjunct to Helicobacter pylori eradication therapy. It is taken as an oral tablet. As a P-CAB, vonoprazan offers a rapid and potent acid suppression profile, providing a new therapeutic option for patients with acid-related disorders.